PMID: 9547134Apr 18, 1998Paper

A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice

International Clinical Psychopharmacology
L EkseliusG Eberhard

Abstract

The purpose of this double-blind, multicenter trial was to compare the efficacy and safety of sertraline (50-150 mg/day) with those of citalopram (20-60 mg/day) in patients with major depression in general practice during 24 weeks of treatment. The patients were assessed using the Montgomery-Asberg Depression Rating Scale and the Clinical Global Impressions of severity and improvement scales. Observed and spontaneously reported adverse events were recorded and side-effects were assessed by means of the UKU Side-Effect Scale. Altogether 400 patients were randomized into the study. A total of 308 patients completed the 24-week study in accordance with the protocol. A significant reduction in the total Montgomery-Asberg Depression Rating Scale scores was observed in both treatment groups as early as 2 weeks, with no statistically significant differences between the drugs. In the intention to treat-last observation carried forward analysis 76% responded to treatment in the sertraline and 81% in the citalopram group. The final mean doses were 82 mg/day (64% higher than baseline) in the sertraline group and 34 mg/day (70% higher than baseline) in the citalopram group. The response rate in completers in accordance with protocol was 90...Continue Reading

Citations

Nov 5, 2002·Depression and Anxiety·A John RushWilliam E Heydorn
Jan 30, 2002·Depression and Anxiety·David L DunnerS D Friedman
Nov 14, 2000·Biological Psychiatry·L J Siever
Jun 5, 2003·Journal of Affective Disorders·Mia Ramklint, Lisa Ekselius
May 18, 2001·Family Practice·U FreudensteinN Donner-Banzhoff
Mar 1, 2009·International Clinical Psychopharmacology·David V Sheehan, Kunitoshi Kamijima
Apr 6, 2000·Psychosomatics·L M ArnoldJ A Welge
Sep 7, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·D van West, M Maes
Feb 25, 2014·Frontiers in Neuroendocrinology·David J Lyons, Christian Broberger
Dec 18, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ursula ReichenpfaderBradley N Gaynes
Aug 7, 2014·Indian Journal of Pharmacology·Kubilay OransaySule Kalkan
Jun 5, 2003·Expert Opinion on Investigational Drugs·Joyce Davidson, Throstur Bjorgvinsson
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P J GoodnickS Arcey
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Mace, D Taylor
May 5, 2001·Expert Opinion on Pharmacotherapy·B G Pollock
Mar 6, 2004·Bipolar Disorders·Benjamin J D H Chun, David L Dunner
May 12, 2010·Alimentary Pharmacology & Therapeutics·P JanssenJ Tack
Nov 4, 2000·The American Journal of Medicine·C D MulrowK Stamm
Nov 20, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jorge Alberto Costa e Silva
Jun 10, 2010·Health and Quality of Life Outcomes·Valerie S L WilliamsDouglas Feltner
Jun 10, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·George I Papakostas, Maurizio Fava
Aug 23, 2011·Journal of Affective Disorders·Janet L CunninghamLisa Ekselius
Mar 4, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·David DevosLuc Defebvre
Sep 14, 2016·Human Brain Mapping·Bernadet L KlaassensJoop M A van Gerven
Jan 5, 2000·The Australian and New Zealand Journal of Psychiatry·T GeorgeJ W Tiller
Oct 31, 2002·Human Psychopharmacology·Andre F. JoubertFrank Larsen
Oct 31, 2002·Human Psychopharmacology·Johan A. Den BoerBernhard R. Slaap
Jun 4, 2005·International Clinical Psychopharmacology·Charles SheltonPhillip E Vinall
Jan 5, 2000·The British Journal of Psychiatry : the Journal of Mental Science·L Ekselius, L Von Knorring
Apr 16, 2010·The Cochrane Database of Systematic Reviews·Andrea CiprianiCorrado Barbui
Jul 13, 2012·The Cochrane Database of Systematic Reviews·Andrea CiprianiCorrado Barbui
Dec 24, 2010·Clinical Schizophrenia & Related Psychoses·Kandi FelmetJohn W Kasckow
Jun 22, 2000·The Annals of Pharmacotherapy·N G Parker, C S Brown
Dec 16, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·George I Papakostas, Maurizio Fava
Sep 2, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gerald GartlehnerKathleen N Lohr

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.